Rollins receives $6 million grant from Gilead’s HIV initiative
Emory’s Rollins School of Public Health has announced a $6 million grant from Gilead Sciences, Inc. over three years to continue to build the capacity of organizations working on the frontlines of the HIV crisis in communities across the Southern United States.
Emory will serve as one of four Gilead COMPASS coordinating centers alongside the Southern AIDS Coalition, the University of Houston Graduate College of Social Work, and Wake Forest School of Divinity to provide direct support to local community organizations to help mitigate the HIV epidemic in the South.
This is part of a second wave of funding from Gilead, manufacturer of antiretroviral therapies for HIV/AIDS. Emory’s COMPASS coordinating center has directly distributed more than $4.3 million to 104 community organizations, and is directed by Neena Smith-Bankhead, director of capacity building and community engagement. More information here.
A recent comprehensive, prospective study of smoking habits among patients with non-small cell lung cancer demonstrated a high rate of smoking reduction and cessation following entry into the phase 3 early-stage trial.
E-Mail
(DENVER February 1, 2021, 10:00 a.m. EST) The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction and cessation following study entry, according to research published today in the
Journal of Thoracic Oncology. The
JTO is the official journal of the International Association for the Study of Lung Cancer.
Continued smoking after a lung cancer diagnosis is associated with an approximate 50% median increase in mortality , according to the 2014 Report of the Surgeon General.
Dr. Conor Steuer, Winship Cancer Institute of Emory University in Atlanta, and colleagues performed prospective assessments evaluating the patterns of tobacco use and cessation and the effects on outcomes. The study was done as part of the ECOG-ACRIN 1505 trial, which sought to determine whether the addition of bevacizumab to adjuvant chem